[go: up one dir, main page]

DE60315666D1 - Furopyridin- und furopyrimidinderivate zur behandlung von hyperproliferativen erkrankungen - Google Patents

Furopyridin- und furopyrimidinderivate zur behandlung von hyperproliferativen erkrankungen

Info

Publication number
DE60315666D1
DE60315666D1 DE60315666T DE60315666T DE60315666D1 DE 60315666 D1 DE60315666 D1 DE 60315666D1 DE 60315666 T DE60315666 T DE 60315666T DE 60315666 T DE60315666 T DE 60315666T DE 60315666 D1 DE60315666 D1 DE 60315666D1
Authority
DE
Germany
Prior art keywords
furopyridine
hyperproliferative
illnesses
treatment
furopyrimidine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60315666T
Other languages
English (en)
Other versions
DE60315666T2 (de
Inventor
Chengzhi Zhang
Gaetan Ladouceur
Michael J Burke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Application granted granted Critical
Publication of DE60315666D1 publication Critical patent/DE60315666D1/de
Publication of DE60315666T2 publication Critical patent/DE60315666T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60315666T 2002-07-11 2003-07-11 Furopyridin- und furopyrimidinderivate zur behandlung von hyperproliferativen erkrankungen Expired - Fee Related DE60315666T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39506502P 2002-07-11 2002-07-11
US395065P 2002-07-11
PCT/US2003/021688 WO2004007502A1 (en) 2002-07-11 2003-07-11 Furopyridine and furopyrimidine derivatives for the treatment of hyper-proliferative disorders

Publications (2)

Publication Number Publication Date
DE60315666D1 true DE60315666D1 (de) 2007-09-27
DE60315666T2 DE60315666T2 (de) 2008-05-08

Family

ID=30115806

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60315666T Expired - Fee Related DE60315666T2 (de) 2002-07-11 2003-07-11 Furopyridin- und furopyrimidinderivate zur behandlung von hyperproliferativen erkrankungen

Country Status (8)

Country Link
US (2) US7429584B2 (de)
EP (1) EP1534715B1 (de)
JP (1) JP2005533109A (de)
AU (1) AU2003256491A1 (de)
CA (1) CA2491077A1 (de)
DE (1) DE60315666T2 (de)
ES (1) ES2291690T3 (de)
WO (1) WO2004007502A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101061101B (zh) * 2003-12-22 2011-09-07 巴斯利尔药物股份公司 芳酰基呋喃和芳酰基噻吩
WO2005087778A1 (en) * 2004-02-16 2005-09-22 Bayer Pharmaceuticals Corporation Tricyclic furopyridine derivatives useful in the treatment of hyper-proliferative disorders
US7674907B2 (en) * 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
CN112608327B (zh) * 2021-01-28 2021-11-02 河南大学 呋喃并喹啉衍生物、其制备方法及应用
CN117003760B (zh) * 2023-07-07 2025-10-03 广东工业大学 一种喹啉稠环衍生物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE107287C (de) *
DD107287A1 (de) * 1973-08-01 1974-07-20
US5137879A (en) * 1990-03-30 1992-08-11 Dowelanco Furopyrimidin-4-imine derivatives
DK0682027T3 (da) 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning
GB9915437D0 (en) * 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III

Also Published As

Publication number Publication date
AU2003256491A1 (en) 2004-02-02
US20090143412A1 (en) 2009-06-04
EP1534715A1 (de) 2005-06-01
JP2005533109A (ja) 2005-11-04
DE60315666T2 (de) 2008-05-08
CA2491077A1 (en) 2004-01-22
EP1534715B1 (de) 2007-08-15
US20060040960A1 (en) 2006-02-23
US7429584B2 (en) 2008-09-30
WO2004007502A1 (en) 2004-01-22
ES2291690T3 (es) 2008-03-01

Similar Documents

Publication Publication Date Title
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
EP1482962A4 (de) Verfahren zur behandlung von trx-vermittelten erkrankungen
DE60232104D1 (de) Nahrungsergänzung zur Behandlung von Makula Degeneration
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
EP1274444A4 (de) Arzneistoffe zur behandlung psychiatrischer oder abusus-bedingter störungen
DE60138129D1 (de) Apparat zur behandlung von zähnen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60232251D1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
ATE358669T1 (de) Pyrazolderivate zur behandlung von hiv
ATE419830T1 (de) Methoden und darreichungsformen zur kontrollierten freisetzung von oxykodon
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60301350D1 (de) Verfahren zur herstellung von 7-substituierten -3-chinolin und 3-chinol-4-on carbonitrile
EP1651164A4 (de) Zusammensetzung und verfahren zur behandlung von neurologischen erkrankungen
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE60132600D1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
SG116507A1 (en) Pharmaceutical dosage form and method of making.
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
EP1651237A4 (de) Verfahren zur behandlung von dermatologischen erkrankungen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60233740D1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee